Proprietary drug delivery SYSTEM

TesoRx has developed an advanced drug delivery system (DDS) that reformulates known molecules into highly effective new therapies. Its proliposomal technology overcomes formulation challenges of drugs that are poorly water-soluble, have low membrane permeability, have a high rate of metabolism or cause systemic toxicity. The DDS is highly customizable and has been successfully applied to both solid and liquid therapies.

The underlying technology was created by TesoRx co-founder, Dr. Guru Betageri, and exclusively licensed from Western University of Health Sciences (WUHS) in Pomona, California. Ongoing application of this DDS for new drug candidates takes place in TesoRx's comprehensive wet lab at the TesoRx Centre of Excellence. 

TesoRx has applied this DDS for its own products and has made it available to pharmaceutical companies reformulating legacy products or developing new ones.

ORAL DELIVERY of testosterone

The main challenge with the oral delivery of Testosterone is the high first pass metabolism of the molecule in the gastrointestinal tract, which prevents systemic uptake of the hormone in the body. Testosterone is also not water soluble and has proven to be extremely difficult to administer in a safe and efficacious manner.

Utilizing TesoRx's DDS, Testosterone Undecanoate (TU) is reformulated as a solid proliposomal powder that is encased in an enteric coated capsule. The capsule bypasses gastric degradation in the stomach and releases the contents in the small intestines. Once released, liposomes containing TU spontaneously form and are absorbed directly into the GI lymphatic system. By bypassing the liver, the DDS allows for excellent oral bioavailability of the drug.

Read more about TesoRx's oral Testosterone products for Hypogonadism in men and Constitutional Delay in Growth and Puberty for boys.


LIPAC Oncology, a subsidiary of TesoRx Pharma, is leveraging a proliposomal intravesical paclitaxel (PLIP) formulation to pursue targeted uro-chemotherapeutics. LIPAC’s lead candidate, TBC-1002, is in development for intravesical administration in the treatment of non-muscle invasive bladder cancer (NMIBC).  Additional indications include Upper Tract Urothelial Carcinoma, Stage II/III Ovarian Cancer and Peritoneal Carcinoma.

Chemotherapy agents are sometimes delivered intravesically (direct instillation into the bladder) or intraperitoneally (into the abdominal cavity) during or following cancer surgery to improve patient outcomes. These agents are not approved for this use and have limitations in efficacy, formulation, and in some cases supply.

Paclitaxel, an agent known to be highly active in systemic application for urothelial carcinomas, is lipophilic and not solubilized in the acidic environment of the bladder. Paclitaxel has not been formulated or approved to be used intravesically in its current formulation. By utilizing LIPAC’s advanced drug delivery platform to enhance permeation and solubility, TBC-1002 overcomes these barriers and represents a breakthrough in the intravesical delivery of paclitaxel. LIPAC has conducted preclinical and clinical studies which demonstrated the superior efficacy of this approach.

Read more about how this technology is applied to TesoRx's Bladder Cancer product.